Teladoc Health Valuation
Is 0LDR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0LDR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0LDR ($9.21) is trading below our estimate of fair value ($27.11)
Significantly Below Fair Value: 0LDR is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0LDR?
Key metric: As 0LDR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 0LDR's PS Ratio? | |
|---|---|
| PS Ratio | 0.6x |
| Sales | US$2.59b |
| Market Cap | US$1.59b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.7x |
| Enterprise Value/EBITDA | 29.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 0LDR's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.2x | ||
EMIS EMIS Group | 7x | 4.8% | UK£1.2b |
CRW Craneware | 5.2x | 8.1% | UK£779.4m |
INS Instem | 3.2x | 11.4% | UK£199.6m |
OPT Optima Health | 1.3x | 1.7% | UK£144.7m |
0LDR Teladoc Health | 0.6x | 0.8% | US$1.6b |
Price-To-Sales vs Peers: 0LDR is good value based on its Price-To-Sales Ratio (0.6x) compared to the peer average (3.2x).
Price to Sales Ratio vs Industry
How does 0LDR's PS Ratio compare vs other companies in the European Healthcare Services Industry?
| 4 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 4 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: 0LDR is good value based on its Price-To-Sales Ratio (0.6x) compared to the European Healthcare Services industry average (2.3x).
Price to Sales Ratio vs Fair Ratio
What is 0LDR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.6x |
| Fair PS Ratio | 2.6x |
Price-To-Sales vs Fair Ratio: 0LDR is good value based on its Price-To-Sales Ratio (0.6x) compared to the estimated Fair Price-To-Sales Ratio (2.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$9.21 | US$10.62 +15.4% | 16.0% | US$14.00 | US$8.00 | n/a | 21 |
| Nov ’25 | US$9.17 | US$10.40 +13.5% | 15.5% | US$14.00 | US$8.00 | n/a | 20 |
| Oct ’25 | US$8.98 | US$9.95 +10.9% | 20.3% | US$17.00 | US$8.00 | n/a | 20 |
| Sep ’25 | US$7.33 | US$9.76 +33.2% | 21.0% | US$17.00 | US$8.00 | n/a | 21 |
| Aug ’25 | US$8.74 | US$12.38 +41.7% | 36.9% | US$25.00 | US$8.00 | n/a | 21 |
| Jul ’25 | US$9.41 | US$16.52 +75.6% | 24.0% | US$25.00 | US$10.00 | n/a | 21 |
| Jun ’25 | US$11.23 | US$16.76 +49.3% | 22.5% | US$25.00 | US$10.00 | n/a | 21 |
| May ’25 | US$12.86 | US$17.38 +35.1% | 19.1% | US$25.00 | US$12.00 | n/a | 22 |
| Apr ’25 | US$15.23 | US$20.36 +33.8% | 17.8% | US$28.00 | US$16.00 | n/a | 22 |
| Mar ’25 | US$15.08 | US$20.52 +36.1% | 17.7% | US$28.00 | US$16.00 | n/a | 21 |
| Feb ’25 | US$19.83 | US$23.03 +16.1% | 18.7% | US$34.00 | US$16.00 | n/a | 20 |
| Jan ’25 | US$21.60 | US$22.80 +5.5% | 20.8% | US$34.00 | US$16.00 | n/a | 19 |
| Dec ’24 | US$18.83 | US$22.80 +21.1% | 20.8% | US$34.00 | US$16.00 | n/a | 19 |
| Nov ’24 | US$16.52 | US$23.54 +42.5% | 21.9% | US$34.00 | US$16.00 | US$9.17 | 19 |
| Oct ’24 | US$18.55 | US$29.54 +59.3% | 16.1% | US$40.00 | US$20.00 | US$8.98 | 19 |
| Sep ’24 | US$22.94 | US$30.11 +31.3% | 13.8% | US$40.00 | US$25.00 | US$7.33 | 21 |
| Aug ’24 | US$27.90 | US$30.06 +7.7% | 14.0% | US$40.00 | US$25.00 | US$8.74 | 21 |
| Jul ’24 | US$25.45 | US$30.35 +19.2% | 12.6% | US$40.00 | US$25.00 | US$9.41 | 22 |
| Jun ’24 | US$23.92 | US$30.40 +27.1% | 12.5% | US$40.00 | US$25.00 | US$11.23 | 22 |
| May ’24 | US$26.73 | US$30.30 +13.4% | 13.0% | US$40.00 | US$23.00 | US$12.86 | 22 |
| Apr ’24 | US$25.65 | US$30.08 +17.3% | 13.8% | US$40.00 | US$23.00 | US$15.23 | 21 |
| Mar ’24 | US$26.11 | US$31.08 +19.0% | 13.2% | US$40.00 | US$25.00 | US$15.08 | 21 |
| Feb ’24 | US$29.36 | US$32.21 +9.7% | 14.9% | US$45.00 | US$24.00 | US$19.83 | 22 |
| Jan ’24 | US$23.10 | US$32.83 +42.1% | 14.6% | US$45.00 | US$24.00 | US$21.60 | 24 |
| Dec ’23 | US$28.64 | US$32.95 +15.1% | 14.6% | US$45.00 | US$24.00 | US$18.83 | 24 |
| Nov ’23 | US$29.30 | US$33.04 +12.8% | 14.6% | US$45.00 | US$24.00 | US$16.52 | 24 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Axogen
US$548.8m
Develops and commercializes technologies for peripheral nerve regeneration and repair worldwide.
0HKD
US$12.49
7D
1.2%
1Y
112.1%
Fagron
€1.4b
A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.
0HNZ
€18.61
7D
-1.4%
1Y
6.7%
Elevance Health
US$94.4b
Operates as a health benefits company in the United States.
0HG8
US$401.96
7D
-5.3%
1Y
-13.1%